Meta-Analysis
Copyright ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Mar 6, 2022; 10(7): 2184-2193
Published online Mar 6, 2022. doi: 10.12998/wjcc.v10.i7.2184
Prognostic value of YKL-40 in colorectal carcinoma patients: A meta-analysis
Jian Wang, Shi Qi, Yu-Bing Zhu, Lei Ding
Jian Wang, Yu-Bing Zhu, Lei Ding, Colorectal Cancer Center, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, China
Shi Qi, Department of Oncology, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, China
Author contributions: Ding L made the substantial contributions to the conception and design of the work; Wang J and Qi S searched, selected materials and extracted data, wrote this manuscript; Zhu YB revised the paper carefully and also contributed to the statistical analysis; Wang J and Qi S contributed equally to this work; all authors have read and approved the final manuscript.
Conflict-of-interest statement: The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
PRISMA 2009 Checklist statement: This systematic review and meta-analysis were conducted according to the Preferred reporting items for systematic reviews and meta-analyses guidelines[29].
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Lei Ding, MD, Professor, Colorectal Cancer Center, Beijing Shijitan Hospital, Capital Medical University, No. 10 Tieyi Road, Haidian District, Beijing 100038, China. dinglei1005@126.com
Received: October 5, 2021
Peer-review started: October 5, 2021
First decision: October 22, 2021
Revised: October 25, 2021
Accepted: January 25, 2022
Article in press: January 25, 2022
Published online: March 6, 2022
Processing time: 148 Days and 3.7 Hours
ARTICLE HIGHLIGHTS
Research background

The predictive role of YKL-40 for long-term survival in colorectal cancer patients has been gradually investigated in recent years.

Research motivation

Whether it is a reliable and valuable prognostic indicator in patients with colorectal carcinoma has not been certified.

Research objectives

To verify the prognostic value of serum/plasma concentration of YKL-40 or expression status of YKL-40 in tumor cells in colorectal carcinoma.

Research methods

Several electronic databases were searched to identify relevant articles. The hazard ratio with 95% confidence interval was combined to the evaluate the association between YKL-40 and overall survival (OS) and progression-free survival (PFS).

Research results

YKL-40 was significantly associated with poor OS (P < 0.001) and PFS (P = 0.001). Subgroup analysis stratified by the treatment, tumor type and source of YKL-40 showed similar results.

Research conclusions

Elevated serum/plasma concentration of YKL-40 or positive expression in tumor cells was related with worse prognosis of colorectal carcinoma patients.

Research perspectives

YKL-40 might serve as a novel and reliable indicator for the evaluation of prognosis in colorectal cancer.